Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Dr. Reddy's Laboratories Limited (RDY)

55.92   0.92 (1.67%) 06-26 18:53
Open: 55.17 Pre. Close: 55
High: 56.055 Low: 55.17
Volume: 161,415 Market Cap: 9,280(M)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and commercialization of differentiated formulations for dermatology and neurology therapeutic areas. The Others segment engages in developing therapies in the fields of oncology and inflammation. As of March 31, 2021, it had three late stage projects at various stages of development. Its therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 56.12 - 56.33 56.33 - 56.5
Low: 54.69 - 54.96 54.96 - 55.17
Close: 55.52 - 55.93 55.93 - 56.26

Technical analysis

as of: 2022-06-24 4:42:45 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 66.19     One year: 77.31
Support: Support1: 54.06    Support2: 52.45
Resistance: Resistance1: 56.66    Resistance2: 66.19
Pivot: 54.7
Moving Average: MA(5): 54.78     MA(20): 54.92
MA(100): 54.28     MA(250): 60.22
MACD: MACD(12,26): 0.2     Signal(9): 0.2
Stochastic oscillator: %K(14,3): 69.4     %D(3): 59.8
RSI: RSI(14): 56.8
52-week: High: 75.5  Low: 47.88
Average Vol(K): 3-Month: 201 (K)  10-Days: 217 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ RDY ] has closed below upper band by 12.0%. Bollinger Bands are 48.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Sat, 25 Jun 2022

Sat, 25 Jun 2022

Fri, 24 Jun 2022
Dr. Reddys Labs (RDY) Acquires Injectable Product Portfolio from Eton Pharma (ETON) -

Tue, 21 Jun 2022
Do Traders Think Dr Reddy's Laboratories Ltd (RDY) Can Keep Climbing Tuesday? - InvestorsObserver

Thu, 16 Jun 2022
ReadyTech to bolster government software capabilities with $23.1 million purchase of IT Vision - Business News Australia

Tue, 14 Jun 2022

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 6,120 (M)
Shares Float 0 (M)
% Held by Insiders 1.6588e+008 (%)
% Held by Institutions 1.1735e+008 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS 1.57
EPS Est Next Qtl 0
EPS Est This Year 1.2
EPS Est Next Year 1.8
Book Value (p.s.) 469.7
Profit Margin (%) 12.6
Operating Margin (%) 16.7
Return on Assets (ttm) 8.1
Return on Equity (ttm) 14.6
Qtrly Rev. Growth 7.9
Gross Profit (p.s.) 16.84
Sales Per Share 33.87
EBITDA (p.s.) 7.5
Qtrly Earnings Growth 3
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio 35.61
PEG Ratio -13.5
Price to Book value 0.11
Price to Sales 1.65
Price to Cash Flow 3.4223e+011

Stock Dividends

Dividend 1.37e+006
Forward Dividend 994080
Dividend Yield 2449930%
Dividend Pay Date 2021-08-10
Ex-Dividend Date 2021-07-07
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.